Published in Pharma Law Weekly, August 24th, 2004
For the quarter ended June 30, 2004, the company reported a net loss of $60.6 million or $0.68 per share, compared to a net loss of $66.7 million or $0.76 per share for the same period in 2003.
The net loss for the second quarter of 2004 included a $17.2 million charge for the write-off of intangible assets for technology and intellectual property in the field of catalytic antibodies. The net loss for the second quarter of 2003 included a charge of $28 million resulting from Abgenix's cancellation of a previous manufacturing agreement with Lonza.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly